Experience of human normal immunoglobulin (Privigen, CSL BEHRING) administration in patients with Guillain - Barre syndrome in non-specialized neurological department
https://doi.org/10.15372/SSMJ20180413
Abstract
Objective - to assess the own experience of human normal immunoglobulin (Privigen, CSL Behring) administration in patients with Guillain - Barre syndrome. Material and methods. Clinical cases of patients with Guillain - Barre syndrome treated with human normal immunoglobulin (Privigen) in 2016-2017. Guillain - Barre syndrome corresponded to the disease clinical and diagnostic criteria. Efficiency of this treatment was considered by improvement of motor and pelvic functions. Besides, side effects and tolerability were assessed clinically. Results. 3 GBS patients underwent treatment. There was improvement of varying degrees in 3 cases, which included improvement in motor sphere and improvement in urination. One case was fatal because of pulmonary and cardiac failure caused by pneumonia. Expected slight side effect was in 1 case, which includes nasopharyngitis, was treated in within days. Conclusion. Results of implementation of human normal immunoglobulin (Privigen, CSL Behring) were ambiguous.
About the Authors
L. P. Smertina
Surgut District Clinical Hospital; Surgut State University
Russian Federation
Russian Federation
V. Z. Movsumov
Surgut District Clinical Hospital; Surgut State University
Russian Federation
Russian Federation
References
1. Попелянский Я.Ю. Болезни периферической нервной системы. Руководство для врачей. 3-е изд., перераб. и доп. М.: Медицина, 2015. 464 с.
2. Пирадов М.А. Синдром Гийена - Барре М.: Интермедика, 2003. 240 с.
3. Пирадов М.А., Супонева Н.А. Синдром Гийена - Барре: диагностика и лечение. Руководство для врачей. М.: МЕДпресс-информ, 2011. 200 с.
4. Супонева Н.А., Пирадов М.А. Внутривенная иммунотерапия в неврологии. М.: Горячая линия - Телеком, 2013. 312 с.
5. Шнайдер Н.А., Кантимирова Е.А. Паранеопластическая полинейропатия: дефиниция, этиопатогенез, диагностика // Сиб. мед. обозрение. 2010. 1. (1). 12-16.
6. Яхно Н.Н., Штульман Д.Р. Болезни нервной системы: в 2 т. Руководство для врачей. М.: Медицина, 2001. 1. 59.
7. Acute onset flaccid paralysis. Geneva: World Health Organization, 1993. http://apps.who.int/iris/handle/10665/61626.
8. Siani B., Willimann K., Wymann S., Marques A., Widmer E. Isoagglutinin reduction in human immunoglobulin products by donor screening // Biol. Ther. 2014. 4. (1). 15-26.
9. Sridhar G., Ekezue B.F., Izurieta H.S., Selvam N., Ovanesov M.V., Divan H.A., Liang Y., Golding B., Forshee R.A., Anderson S.A., Menis M. Immune globulins and same-day thrombotic events as recorded in a large health care database during 2008 to 2012 // Transfusion. 2014. 54. (10). 53-65
10. Skoda-Smith S., Torgerson T.R., Ochs H.O. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease // Ther. Clin. Risk Manag. 2010. 6. 1-10.
Review
Views:
348
Email this article 